Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine

American Journal of Hematology

Volumn 88, Issue 9, 2013, Pages 780-783

  Cluzeau, Thomas ^a,b   Mounier, Nicolas ^b   Karsenti, Jean Michel ^b   Richez, Valentine ^b   Legros, Laurence ^b,c   Gastaud, Lauris ^d   Garnier, Georges ^e   Re, Daniel ^f   Montagne, Nathalie ^g   Gutnecht, Jean ^h   Gabriel Fuzibet, Jean ^b   Auberger, Patrick ^a   Raynaud, Sophie ^b   Cassuto, Jill Patrice ^b  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c CNRS   (France)

^d Centre Lacassagne   (France)

^e CHPG   (Monaco)

^f CH Antibes ^*  (France)

^g Service médecine interne   (France)

^h Centre Hospitalier Intercommunal de Frejus Saint Raphael   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MONOSOMAL KARYOTYPE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; KARYOTYPE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONOSOMY; MYELODYSPLASTIC SYNDROMES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84882649424     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23509     Document Type: Article

References (21)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. New England J Med 2009;361:1872-1885.
2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-951.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
4. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510.
5. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361.
6. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012;120:2454-2465.
7. Warlick ED, Hirsch BA, Nguyen PL, et al. Comparison of IPSS and IPSS-R Scoring in a Population Based Myelodysplastic Syndromes (MDS) Study. ASH Annual Meeting Abstracts 2012;120:3841-
8. Messa E, Gioia D, Evangelista A, et al. High predictive value of the revised international prognostic scoring system (IPSS-R): An external analysis of 646 patients from a multiregional Italian MDS registry. ASH Annual Meeting Abstracts 2012;120:1702-
9. Gangat N, Patnaik MM, Begna K, et al. Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. Am J Hematol 2013.
10. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008;26:4791-4797.
11. Patnaik MM, Hanson CA, Hodnefield JM, et al. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia 2011;25:266-270.
12. Ahn HK, Jang JH, Kim K, et al. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. Am J Hematol 2012;87:37-41.
13. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
14. Lamarque M, Raynaud S, Itzykson R, et al. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: The GFM experience. Blood 2012;120:5084-5085.
15. Itzykson R, Thepot S, Eclache V, et al. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia 2011;25:1207-1209.
16. Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403-411.
17. Chia NL. A comprehensive set of idiograms representing all interpretive levels of resolution: ISCN (2009). Cytogenet Genome Res 2009;125:162-164.
18. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425.
19. Valcarcel D, Adema V, Sole F, et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol 2013;31:916-922.
20. Belli CB, Bengio R, Aranguren PN, et al. Partial and total monosomal karyotypes in myelodysplastic syndromes: Comparative prognostic relevance among 421 patients. Am J Hematol 2011;86:540-545.
21. Kayser S, Zucknick M, Dohner K, et al. Monosomal karyotype in adult acute myeloid leukemia: Prognostic impact and outcome after different treatment strategies. Blood 2012;119:551-558.